Status:
UNKNOWN
Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients
Lead Sponsor:
Taipei Medical University Hospital
Conditions:
Nonalcoholic Fatty Liver Disease (NAFLD)
Eligibility:
All Genders
20-65 years
Brief Summary
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver biochemistry tests in the world. The prevalence rate of NAFLD has been reported to be 30-40% in men and 15-20% in wo...
Detailed Description
This prospective study have been approved by Taipei Medical University-Joint Institutional Review Board. The starting point for each patient is the day of surgery and the end-point is 1 year after the...
Eligibility Criteria
Inclusion
- Adult male and female Morbidly obese patients age 20-65 years with BMI over 37.5 kg/m\^2, or BMI over 32.5 kg/m\^2 with comorbidity other than diabetes (hypertension, NASH, dyslipidemia, obstructive sleep apnea, osteoarthritis joint…etc.) or BMI over 27.5 kg/m\^2 with poor control diabetes undergoing bariatric surgery
Exclusion
- The presence of end organ damage
- Previous bariatric surgery
- Women who are pregnant or nursing
- Prolonged exposure to known hepatotoxins such as alcohol or drugs
- Concurrent hepatitis B virus, hepatitis C virus, hepatitis D virus, or human immunodeficiency virus infection
- Concurrent autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis
- Wilson disease or hemochromatosis
Key Trial Info
Start Date :
October 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04059029
Start Date
October 1 2016
End Date
July 1 2021
Last Update
August 16 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.